Comparison of the Efficacy and Safety of Fixed-Dose Amlodipine/Losartan and Losartan in Hypertensive Patients Inadequately Controlled with Losartan A Randomized, Double-Blind, Multicenter Study

被引:16
作者
Hong, Bum-Kee [2 ]
Park, Chang Gyu [3 ]
Kim, Ki Sik [4 ]
Yoon, Myeong Ho [5 ]
Yoon, Ho Joong [6 ]
Yoon, Jeong Han [7 ]
Yang, Joo Young [8 ]
Choi, Young Jin [9 ]
Cho, Seung Yun [1 ]
机构
[1] Yonsei Univ, Coll Med, Cardiovasc Hosp, Div Cardiol, Seoul 120752, South Korea
[2] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Ctr Heart, Seoul, South Korea
[3] Korea Univ, Guro Hosp, Div Cardiol, Seoul, South Korea
[4] Daegu Catholic Univ, Med Ctr, Div Cardiol, Taegu, South Korea
[5] Ajou Univ, Med Ctr, Div Cardiol, Suwon, South Korea
[6] Catholic Univ, Seoul St Mary Hosp, Div Cardiol, Seoul, South Korea
[7] CHA Univ, CHA Bundang Med Ctr, Div Cardiol, Songnam, Gyeonggi Do, South Korea
[8] Ilsan Hosp, Natl Hlth Insurance Corp, Dept Cardiol, Ilsan, South Korea
[9] Hallym Univ, Med Ctr, Hanging Sacred Heart Hosp, Div Cardiol, Seoul, South Korea
关键词
AMLODIPINE/VALSARTAN COMBINATION THERAPY; RECEPTOR ANTAGONIST; BLOOD-PRESSURE; PHARMACOKINETICS; TOLERABILITY; PREVENTION; VALSARTAN; OUTCOMES; TRIAL;
D O I
10.2165/11597410-000000000-00000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fixed-dose combination drugs may enhance blood pressure (BP) goal attainment through complementary effects and reduced side effects, which leads to better compliance. Objective: This study aimed to evaluate the efficacy and safety profiles of once-daily combination amlodipine/losartan versus losartan. Methods: This was an 8-week, double-blind, multicenter, randomized phase III study conducted in outpatient hospital clinics. Korean patients with essential hypertension inadequately controlled on losartan 100 mg were administered amlodipine/losartan 5 mg/100 mg combination versus losartan 100 mg. The main outcome measures were changes in sitting diastolic blood pressure (DBP) and sitting systolic blood pressure (SBP) and BP response rate from baseline values, which were assessed after 4 and 8 weeks of treatment. Safety and tolerability were also assessed. Results: At week 8, both groups achieved significant reductions from baseline in DBP (11.7 +/- 7.0 and 3.2 +/- 7.9 mmHg), which was significantly greater in the amlodipine/losartan 5 mg/100 mg combination (n = 70) group (p < 0.0001). Additionally, the amlodipine/losartan 5 mg/100 mg combination group achieved significantly greater reductions in SBP at week 8 and in SBP and DBP at week 4 compared with the losartan 100 mg (n = 72) group (all p < 0.0001). Response rates were significantly higher in the amlodipine/losartan 5 mg/100 mg group versus the losartan 100 mg group (81.4% vs 63.9% at week 4, p < 0.0192; 90.0% vs 66.7% at week 8, p < 0.001). Both treatments were generally well tolerated. Conclusion: Switching to a fixed-dose combination therapy of amlodipine/losartan 5 mg/100 mg was associated with significantly greater reductions in BP and superior achievement of BP goals compared with a maintenance dose of losartan 100 mg in Korean patients with essential hypertension inadequately controlled on losartan 100 mg.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 21 条
[1]   Preserving renal function in adults with hypertension and diabetes: A consensus approach [J].
Bakris, GL ;
Williams, M ;
Dworkin, L ;
Elliott, WJ ;
Epstein, M ;
Toto, R ;
Tuttle, K ;
Douglas, J ;
Hsueh, W ;
Sowers, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (03) :646-661
[2]  
CHOBANIAN AV, 2003, JAMA-J AM MED ASSOC, V289, P2560, DOI DOI 10.1161/01.HYP.0000107251.49515.C2
[3]   The combination of olmesartan medoxomil and Amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study [J].
Chrysant, Steven G. ;
Melino, Michael ;
Karki, Sulekha ;
Lee, James ;
Heyrman, Reinilde .
CLINICAL THERAPEUTICS, 2008, 30 (04) :587-604
[4]   Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial [J].
Dahlöf, B ;
Sever, PS ;
Poulter, NR ;
Wedel, H ;
Beevers, DG ;
Caulfield, M ;
Collins, R ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Östergren, J .
LANCET, 2005, 366 (9489) :895-906
[5]   Comparison of two strategies for intensifying antihypertensive treatment - Low-dose combination (enalapril plus felodipine ER) versus increased dose of monotherapy (enalapril) [J].
Elliott, WJ ;
Montoro, R ;
Smith, D ;
Leibowitz, M ;
Hwang, C ;
Gradman, AH ;
Schleman, N ;
Klibaner, M .
AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (07) :691-696
[6]   Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension [J].
Hilleman, DE ;
Reyes, AP ;
Wurdeman, RL ;
Faulkner, M .
JOURNAL OF HUMAN HYPERTENSION, 2001, 15 (08) :559-565
[7]   Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients [J].
Jamerson, Kenneth ;
Weber, Michael A. ;
Bakris, George L. ;
Dahlof, Bjorn ;
Pitt, Bertram ;
Shi, Victor ;
Hester, Allen ;
Gupte, Jitendra ;
Gatlin, Marjorie ;
Velazquez, Eric J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (23) :2417-2428
[8]   Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J].
Julius, S ;
Kjeldsen, SE ;
Weber, M ;
Brunner, HR ;
Ekman, S ;
Hansson, L ;
Hua, TS ;
Laragh, J ;
McInnes, GT ;
Mitchell, L ;
Plat, F ;
Schork, A ;
Smith, B ;
Zanchetti, A .
LANCET, 2004, 363 (9426) :2022-2031
[9]   Long-term adherence with cardiovascular drug regimens [J].
Kulkarni, SP ;
Alexander, KP ;
Lytle, B ;
Heiss, G ;
Peterson, ED .
AMERICAN HEART JOURNAL, 2006, 151 (01) :185-+
[10]   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].
Lewis, EJ ;
Hunsicker, LG ;
Clarke, WR ;
Berl, T ;
Pohl, MA ;
Lewis, JB ;
Ritz, E ;
Atkins, RC ;
Rohde, R ;
Raz, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860